Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27076
Title: Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.
Austin Authors: Silagy, Andrew W;Kotecha, Ritesh R;Weng, Stanley;Holmes, Arturo;Singla, Nirmish;Mano, Roy;Attalla, Kyrollis;Weiss, Kate L;DiNatale, Renzo G;Patil, Sujata;Coleman, Jonathan A;Motzer, Robert J;Russo, Paul;Voss, Martin H;Hakimi, A Ari
Affiliation: Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
Department of Urology, State University of New York Downstate, New York, New York
Surgery (University of Melbourne)
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
Issue Date: 2021
Date: 2021-07-19
Publication information: Cancer 2021; 127(21): 3946-3956
Abstract: Systemic responses to cytoreductive nephrectomy (CN) in the management of metastatic renal cell carcinoma (mRCC) are variable and difficult to anticipate. The authors aimed to determine the association of CN with modifiable International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors and oncological outcomes. Consecutive patients with mRCC referred for potential CN (2009-2019) were reviewed. The primary outcome was overall survival (OS); variables of interest included undergoing CN and the baseline number of modifiable IMDC risk factors (anemia, hypercalcemia, neutrophilia, thrombocytosis, and reduced performance status). For operative cases, the authors evaluated the effects of IMDC risk factor dynamics, measured 6 weeks and 6 months after CN, on OS and postoperative treatment disposition. Of 245 treatment-naive patients with mRCC referred for CN, 177 (72%) proceeded to surgery. The CN cases had fewer modifiable IMDC risk factors (P = .003), including none in 71 of 177 patients (40.1%); fewer metastases (P = .011); and higher proportions of clear cell histology (P = .012). In a multivariable analysis, surgical selection, number of IMDC risk factors, metastatic focality, and histology were associated with OS. Total risk factors changed for 53.8% and 57.2% of the patients from the preoperative period to 6 weeks and 6 months after CN, respectively. Adjusted for preoperative IMDC risk scores, an increase in IMDC risk factors at 6 weeks and 6 months was associated with adverse OS (hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.13-2.19; P = .007; HR, 2.52; 95% CI, 1.74-3.65; P < .001). IMDC risk factors are dynamic clinical variables that can improve after upfront CN in select patients, and this suggests a systemic benefit of cytoreduction, which may confer clinically meaningful prognostic implications.
URI: https://ahro.austin.org.au/austinjspui/handle/1/27076
DOI: 10.1002/cncr.33790
ORCID: 0000-0002-4990-8445
0000-0002-0223-3479
0000-0001-9495-6983
0000-0001-6925-2327
0000-0003-0551-5807
Journal: Cancer
PubMed URL: 34286865
Type: Journal Article
Subjects: cytoreductive nephrectomy
patient selection
renal cell carcinoma
risk stratification
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Jul 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.